<p><em>Peningkatan jumlah penduduk lansia menjadi tantangan sendiri. Pemenuhan fasilitas, sistem serta peran dari pemerintah dan masyarakat dengan tujuan meningkatkan kualitas hidup lansia.. Salah satu aspek yang terkait dengan proses penuaan adalah penurunan fungsi yang mencakup psikologis, sosiologis dan biologis. Salah satu perubahanan yaitu penurunan fungsi kognitif. Penuruan fungsi pada lansia juga menjadi faktor yang mempengaruhi tingkat kemandirian dari lansia. Tujuan penelitian ini adalah untuk menilai hubungan tingkat kemandirian dan gangguan kognitif pada lansia. Penelitian ini menggunakan desain cross-sectional dengan teknik pengumpulan sampel convenience-sampling. Sampel penelitian ini merupakan pasien prolanis. Pengumpulan data menggunakan kuesioner Moca-Ina versi Indonesia untuk menilai fungsi kognitif dan Indeks Barthel untuk menilai tingkat kemandirian. Untuk menilai keadaan sosiodemografi dinilai melalui wawancara. Hasil penelitian ini didapatkan hasil hubungan tingkat kemandirian dan gangguan kognitif pada lansia dengan hasil p=0.209. Untuk hasil tingkat kemandirian didapatkan hasil tingkat mandiri (92%), fungsi kognitif umumnya berada pada mild kognitif (76%). Dari penelitan ini disimpulkan hubungan tidak bermakna tingkat kemandirian dengan gangguan kognitif.</em></p>
Penggunaan antipsikotik pada penderita skizofrenia memiliki efek blokade reseptor dopaminergik dan serotonergik yang menimbulkan penurunan gejala skizofrenia. Obat ini juga dapat menimbulkan efek samping berupa peningkatan berat badan yang meningkatkan risiko sindroma metabolik dan penyakit kardiovaskular. Penelitian ini bertujuan untuk mengidentifikasi keluhan peningkatan berat badan subjektif pada penderita skizofrenia yang mendapat terapi antipsikotik. Penelitian deskriptif ini menggunakan metode potong lintang dan mengikutsertakan 104 subjek penelitian yang terdiagnosis skizofrenia dan menjalani terapi rawat jalan di RS HB Saanin Padang. Subjek direkrut secara konsekutif sampling setelah memenuhi kriteria inklusi dan eksklusi. Penelitian ini memperoleh hasil bahwa subjek yang mendapat terapi obat atipikal, tipikal, dan kombinasi mengeluhkan peningkatan berat badan subjektif masing-masing sebesar 59,6% , 60,0% dan 53,2%. Pada penelitian ini dapat disimpulkan bahwa terdapat keluhan peningkatan berat badan subjektif pada subjek penelitian yang memperoleh obat antipsikotik terutama golongan atipikal dan kombinasi.
<p class="Englishversionofabstract">Weight-gain is one of the antipsychotic side effects, and it can increase the risk factor of metabolic syndrome. Several studies relate it to increase leptin levels. This research was conducted to determine the profile of leptin levels in schizophrenic patients who were receiving antipsychotic therapy at Prof. DR. HB Saanin Mental Hospital. The research was conducted from November 2019 to January 2020 on schizophrenic patients who were taking antipsychotic drugs. This research was conducted on 50 samples by using consecutive sampling techniques. Data analysis using univariate are presented in geometric mean and CI 95%. Moreover, a Comparison of leptin levels between groups was performed by T-test and one-way ANOVA. The average leptin level from 50 samples of schizophrenic patients was 5.12µg/ml (CI 95%=3.32-7.90). The highest average leptin level is from the 46-55 year age group which is 11.32µg/ml (CI 95% =5.24 - 24.42), female is 13.29µg/ml (CI 95%=5.84-30.26), BMI ≥30kg/m2 is 12.84µg/ml (CI 95%=4.31-38.23), subjects with above-average waist circumference is 5.54µg/ml ( CI 95%=3.45-8.90), and the atypical group of drugs is 6.08µg/ml (IK 95%=3.41-10.84). Increasing levels of leptin occur in schizophrenic patients who were 46-55 y.o, female BMI ≥30kg/m2, above-average waist circumference, and receiving atypical antipsychotics.</p>
Antipsychotic-induced hyperprolactinemia disorder affects the morbidity and quality of life of the patient, and can lower the patient's adherence to taking antipsychotics, thereby lowering the therapeutic success rate. This study aims to figure out the incidence of hyperprolactinemia side effects in schizophrenia patients receiving antipsychotic therapy. This descriptive research was conducted at HB Saanin Psychiatric Hospital Padang in January-June 2018. The population in this study is all schizophrenia patients in the HB. Saanin Psychiatric Hospital Padang Year 2018 and involved participants as many as 100 people recruited in consecutive sampling. Data were analyzed using a descriptive statistical method. The results showed that more than half of the patients were 59 people (59.0%) hyperprolactinemia. Patients with gynecomastia amounted to 16 people (16%). Patients with galactorrhea amounted to 3 people (3%). Patients with sexual dysfunction amounted to 19 people (19%). Male patients amounted to 60 people, 21 people (35%) The sexual dysfunction of female patients amounted to 40 people, 26 people (65%) Menstrual cycle changes. More than half of the Schizophrenia patients receiving antipsychotic therapy in this study suffer symptoms of hyperprolactinemia in the manifestation of galactorrhea, gynecomastia, menstrual disorders, and sexual dysfunction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.